Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026

Get updates on Theralase Technologies Inc. delivered in your email.

Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Level 2 quotes

View:

Post by DJDawg on May 31, 2023 9:19am

Level 2 quotes

The level 2 quotes look pretty much the same as yesterday. The large ask of 100,000 shares sits at 0.265. Otherwise no big new bids.

This tells us that the thing that is determining price action right now is NOT clinical data. The clinical data was very good. In any other biotech company the clinical data would cause a price spike.

It's all about the uncertainty of where the next installment of money may come from.

And the fact that the same pool of people cotinue to be the only ones who know anything about this company. No new buyers showing up yet.

341

Comment

Comment by N0taP00p on May 31, 2023 9:44am

No clarity on what their timeline for submission is, other than being happy about their interim assessment. And no clarity on funding. When will they learn. I am more convinced than ever that BTD won't happen till Q3. Expecting another round of dilution with 10 million shares + 10 million warrants. It'll take them a month minimum to fill it, unless they ...more

253

Comment

Theralase Technologies Inc.

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

Connect with V.TLT

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

FACT SHEET

The Watchlist

< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250

Become a member today, It's free!

Sign In

Send my password